A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07133425 by M.D. Anderson Cancer Center, with a registry enrolment figure of 29 participants, started 2025-11-06 and due to reach its primary completion in 2028-02-01. Interventions recorded: SAR445877. Conditions listed: Non-Small Cell Lung Cancer; ICI-refractory. Primary outcome: Safety and adverse events (AEs). Lung eligibility wording from the registry: "Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment:". Sites: United States. No results are recorded here; the registry entry is the source.